These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Anticoagulants and thrombocyte aggregation inhibitors in or following myocardial infarct]. Rühle H Z Arztl Fortbild (Jena); 1985; 79(11):463-6. PubMed ID: 3901541 [No Abstract] [Full Text] [Related]
6. [Platelet inhibitors or anticoagulants in prevention after myocardial infarct? The 1991 state of the art]. van de Loo J; Kienast J Z Gesamte Inn Med; 1992 Jan; 47(1):1-5. PubMed ID: 1570716 [TBL] [Abstract][Full Text] [Related]
7. [Advantages and hazards of drug treatment in surgery. Anticoagulants and fibrinolytic agents]. Gross R Chirurg; 1968 May; 39(5):201-8. PubMed ID: 4974339 [No Abstract] [Full Text] [Related]
8. [Antithrombotic therapy in acute coronary syndrome]. Chazov EI; Panchenko EP Ter Arkh; 2000; 72(3):65-75. PubMed ID: 10776658 [No Abstract] [Full Text] [Related]
9. [Summary: Secondary prophylaxis following myocardial re-infarct. Anticoagulants or thrombocyte function inhibitors?]. Breddin K; Loeliger EA Internist (Berl); 1980 Jul; 21(7):399. PubMed ID: 7007281 [No Abstract] [Full Text] [Related]
11. A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy -- equivalence of costs as a possible case for oral anticoagulants. Gianetti J; Gensini G; De Caterina R Thromb Haemost; 1998 Dec; 80(6):887-93. PubMed ID: 9869155 [TBL] [Abstract][Full Text] [Related]
12. New thrombolytics, anticoagulants, and platelet antagonists: the future of clinical practice. Becker RC J Thromb Thrombolysis; 1999 Apr; 7(2):195-220. PubMed ID: 10364771 [No Abstract] [Full Text] [Related]
13. Guidelines for the use of thrombolytic therapy. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Ludlam CA; Bennett B; Fox KA; Lowe GD; Reid AW Blood Coagul Fibrinolysis; 1995 May; 6(3):273-85. PubMed ID: 7654941 [No Abstract] [Full Text] [Related]
14. Reduced tissue factor pathway inhibitor-1 after pharmacological thrombolysis: an epiphenomenon or potential culprit in rethrombosis? Shah PK Circulation; 2002 Jan; 105(3):270-1. PubMed ID: 11804975 [No Abstract] [Full Text] [Related]
15. [Treatment of myocardial infarct with anticoagulants, thrombolytics, inhibitors of platelet aggregation and beta receptor blockaders]. Thiele R Z Arztl Fortbild (Jena); 1984; 78(5):167-71. PubMed ID: 6202068 [No Abstract] [Full Text] [Related]
16. [Antithrombotic treatment in atrial fibrillation. Background to new recommendations and therapeutic alternative]. Själander A; Wallentin L; Rosenqvist M; Svensson P Lakartidningen; 2008 Sep 10-16; 105(37):2478-80. PubMed ID: 19006862 [No Abstract] [Full Text] [Related]
17. Antithrombotic therapy in peripheral artery disease--antiplatelet therapy, anticoagulants, both or none. Tangelder MJ; van Hattum ES Thromb Haemost; 2010 Aug; 104(2):196-9. PubMed ID: 20508897 [No Abstract] [Full Text] [Related]
18. [Current use of anti-hemostatics in ischemic cardiopathy]. Bolao IG; Alegría E; Iglesias I; Velasco S; Fidalgo ML; Gómez JA; Huelmos A Rev Med Univ Navarra; 1990; 34(4):219-26. PubMed ID: 2152748 [TBL] [Abstract][Full Text] [Related]
19. Antithrombotic agents and invasive procedures--hematologist point of view. Lecompte TP Thromb Res; 2012 Oct; 130 Suppl 1():S61-2. PubMed ID: 23026666 [TBL] [Abstract][Full Text] [Related]